Hemotune AG
PrivateLast Round
Series B
Extension
Mar 25, 2024
Total Funding Raised
$33.54M
Company Overview
Hemotune AG operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a Series B Extension round in March 2024.
Hemotune AG is a medical devices company that develops a blood purification platform using nanoengineered magnetic beads to selectively remove harmful substances from the bloodstream.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales, Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hemotune AG Comparables
Compare Hemotune AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediSieve | 89% | |
| ExThera Medical | 84% | |
| BOA Biomedical Inc. | 83% |
For institutional investors. Book with your work email.
Hemotune AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Mar 25, 2024 | ||||
| Series B Extension | Apr 26, 2022 | ||||
| Series A | Aug 12, 2020 | ||||
| Grant | Jul 9, 2020 | ||||
| Grant | Feb 1, 2020 | ||||
Accelerator | Jul 5, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hemotune AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gebert Rüf Stiftung | Grant |
| EIT Health | Grant, Series A |
| VP Venture Partners | Series B Extension |
| EFI Lake Geneva Ventures | Series B Extension |
| Wyss Zurich | Grant |
| Belmondo Family Office | Series B Extension |
| Innosuisse | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 25, 2024
$16M round led by Belmondo Family Office
- Apr 26, 2022
$7.6M round led by OCCIDENT.
For institutional investors. Book with your work email.
Hemotune AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hemotune AG's valuation, stock price, and market status.
Is Hemotune AG a public or private company?
Hemotune AG is a private company.
What is the current stock price of Hemotune AG?
Hemotune AG is a private company, so its shares have no public market price. Caplight tracks Hemotune AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hemotune AG worth (valuation)?
Valuation information for Hemotune AG is not publicly available.
Can I buy Hemotune AG stock?
Hemotune AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hemotune AG's last funding round?
Hemotune AG's most recent funding round was Series B Extension on March 25, 2024.
Who are the main investors in Hemotune AG?
Key investors in Hemotune AG include Belmondo Family Office, OCCIDENT.
Will Hemotune AG IPO soon?
No public IPO plans have been announced for Hemotune AG.
How can I track Hemotune AG secondary market activity?
Caplight tracks bids, offers, and trades in Hemotune AG's shares on secondary markets.